{"id":58951,"date":"2026-03-06T16:35:47","date_gmt":"2026-03-06T08:35:47","guid":{"rendered":"https:\/\/flcube.com\/?p=58951"},"modified":"2026-03-06T16:35:48","modified_gmt":"2026-03-06T08:35:48","slug":"roches-petrelintide-hits-10-7-weight-loss-in-phase-ii-zupreme-1-trial-amylin-analog-shows-sustained-efficacy-through-week-42","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58951","title":{"rendered":"Roche’s Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial \u2013 Amylin Analog Shows Sustained Efficacy Through Week 42"},"content":{"rendered":"\n

Roche<\/strong> (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced positive topline results<\/strong> from the Phase II ZUPREME-1 trial<\/strong> evaluating petrelintide<\/strong> in 493 individuals with overweight and obesity<\/strong> (mean BMI 37\u202fkg\/m\u00b2). Participants achieved up to 10.7% mean weight loss from baseline<\/strong> at week 42 versus 1.7% placebo<\/strong>, demonstrating sustained efficacy for the once-weekly amylin analog<\/strong> acquired through the 2025 Zealand Pharma partnership<\/strong>.<\/p>\n\n\n\n

Clinical Trial Results<\/h2>\n\n\n\n
Endpoint<\/th>Petrelintide<\/th>Placebo<\/th>Treatment Effect<\/th><\/tr><\/thead>
Mean Weight Loss (Week 42)<\/strong><\/td>Up to 10.7%<\/td>1.7%<\/td>9.0 percentage-point advantage<\/strong><\/td><\/tr>
Analysis Method<\/strong><\/td>Efficacy estimand<\/td>\u2014<\/td>Accounts for treatment adherence<\/td><\/tr>
Study Population<\/strong><\/td>493 participants<\/td>\u2014<\/td>Mean BMI 37\u202fkg\/m\u00b2 (obese)<\/td><\/tr>
Duration<\/strong><\/td>42 weeks<\/td>\u2014<\/td>Sustained weight loss trend<\/td><\/tr>
Trial Name<\/strong><\/td>ZUPREME-1 (Phase II)<\/td>\u2014<\/td>Randomized, double-blind, placebo-controlled<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Petrelintide Profile<\/th><\/tr><\/thead>
Drug Class<\/strong><\/td>Long-acting amylin analog<\/td><\/tr>
Target<\/strong><\/td>Amylin receptor (co-localized with calcitonin receptor in brainstem)<\/td><\/tr>
Mechanism<\/strong><\/td>Restores leptin sensitivity \u2192 enhanced satiety signaling; slows gastric emptying<\/td><\/tr>
Dosing<\/strong><\/td>Once-weekly subcutaneous injection<\/td><\/tr>
Physiological Role<\/strong><\/td>Mimics pancreatic beta-cell amylin co-secreted with insulin post-prandially<\/td><\/tr>
Differentiation<\/strong><\/td>Novel satiety pathway vs. GLP-1\/GIP incretins; potential for complementary\/combination use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Partnership Context<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Partner<\/strong><\/td>Zealand Pharma (exclusive collaboration)<\/td><\/tr>
Agreement Date<\/strong><\/td>2025<\/td><\/tr>
Structure<\/strong><\/td>Co-development and co-commercialization<\/td><\/tr>
Roche Contribution<\/strong><\/td>Global clinical development infrastructure; commercial scale<\/td><\/tr>
Zealand Contribution<\/strong><\/td>Amylin peptide engineering expertise; IP estate<\/td><\/tr>
Therapeutic Focus<\/strong><\/td>Overweight and obesity (initial); potential expansion to metabolic syndrome<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Positioning & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Strategic Implication<\/th><\/tr><\/thead>
Efficacy Benchmark<\/strong><\/td>10.7% weight loss positions petrelintide competitively vs. early-phase GLP-1 data (semaglutide Phase II: ~12-15%)<\/td><\/tr>
Differentiation<\/strong><\/td>Amylin mechanism offers alternative for GLP-1 intolerant patients; potential for fixed-dose combination with incretins<\/td><\/tr>
Safety Profile<\/strong><\/td>Amylin analogs historically associated with lower GI side effects vs. GLP-1s; nausea\/vomiting rates critical for Phase III design<\/td><\/tr>
Market Timing<\/strong><\/td>Phase III initiation expected 2026; potential 2028-2029 launch amid GLP-1 market maturation<\/td><\/tr>
Revenue Potential<\/strong><\/td>Analysts estimate $5-10 billion peak sales<\/strong> if approved as monotherapy or combination; Zealand Pharma milestone\/royalty structure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Outlook<\/h2>\n\n\n\n